Fig. 6: CYP2J2/EpOME mediates PLEC to promote the progression of TNBC.

A Scheme of the proteomics experimental study; PLS-DA analysis of the proteomes showed the visual separation of MDA-MB-231 (B) and MCF-7 (C) cells upon the treatment with 12(13)-EpOME; D Wein diagram shown the shared DEPs of MDA-MB-231 and MCF-7 cells upon the treatment with 12(13)-EpOME; E, F Volcano plots proposed PLEC as the shared DEP contributing greatly to the separation of proteomes for MDA-MB-231 and MCF-7 cells upon the treatment with 12(13)-EpOME; G Treatment with 12(13)-EpOME visually upregulated PLEC in MDA-MB-231 and MCF-7 cells; H shPLEC significantly decreased the viability of MDA-MB-231 cells, and the cellular viability-promoting effect of 12(13)-EpOME (n = 6); I Scheme of the CDX mice model of TNBC; J shPLEC significantly inhibited the tumor growth and tumor-promoting effect of 12(13)-EpOME in a CDX mice model of TNBC (n = 4 or 5); K Representative images of tumors from the TNBC mice with vehicle cells, and shPLEC MDA-MB-231 cells receiving 12(13)-EpOME treatment and vehicle; shCXCL9 significantly decreased the tumor weight (L) and tumor volume (M), and the tumor-promoting effect of 12(13)-EpOME in a CDX mice model of TNBC (n = 4 or 5); N, O shPLEC significantly decreased the wound healing capacity of MDA-MB-231 cells, and the wound healing-promoting capacity of 12(13)-EpOME (n = 3); P, Q shPLEC significantly decreased the migrative (left) and invasive (right) capability of MDA-MB-231 cells, and the migration-and invasion-promoting capacity of 12(13)-EpOME (n = 3); R Scheme of the CDX mice model of TNBC metastasis; S, T fluorescence imaging showed that shPLEC significantly decreased the lung metastasis of MDA-MB-231 cells and metastasis-promoting effect of 12(13)-EpOME (n = 5); U, V Histological analyses revealed that shPLEC significantly decreased the lung metastasis of MDA-MB-231 cells and metastasis-promoting effect of 12(13)-EpOME (n = 5). Data are presented as Mean ± SD. Statistical analyses were performed as Fig. 3.